Nature Communications (Sep 2022)
Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration
- Ying Jiang,
- John J. Alam,
- Stephen N. Gomperts,
- Paul Maruff,
- Afina W. Lemstra,
- Ursula A. Germann,
- Philip H. Stavrides,
- Sandipkumar Darji,
- Sandeep Malampati,
- James Peddy,
- Cynthia Bleiwas,
- Monika Pawlik,
- Anna Pensalfini,
- Dun-Sheng Yang,
- Shivakumar Subbanna,
- Balapal S. Basavarajappa,
- John F. Smiley,
- Amanda Gardner,
- Kelly Blackburn,
- Hui-May Chu,
- Niels D. Prins,
- Charlotte E. Teunissen,
- John E. Harrison,
- Philip Scheltens,
- Ralph A. Nixon
Affiliations
- Ying Jiang
- Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research
- John J. Alam
- EIP Pharma Inc
- Stephen N. Gomperts
- Massachusetts Alzheimer’s Disease Research Center
- Paul Maruff
- Cogstate Ltd, Runway East Borough Market
- Afina W. Lemstra
- Alzheimer Center Amsterdam, Amsterdam Neuroscience - Neurodegeneration
- Ursula A. Germann
- EIP Pharma Inc
- Philip H. Stavrides
- Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research
- Sandipkumar Darji
- Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research
- Sandeep Malampati
- Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research
- James Peddy
- Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research
- Cynthia Bleiwas
- Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research
- Monika Pawlik
- Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research
- Anna Pensalfini
- Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research
- Dun-Sheng Yang
- Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research
- Shivakumar Subbanna
- Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research
- Balapal S. Basavarajappa
- Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research
- John F. Smiley
- Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research
- Amanda Gardner
- EIP Pharma Inc
- Kelly Blackburn
- EIP Pharma Inc
- Hui-May Chu
- Anoixis Corporation
- Niels D. Prins
- Brain Research Center
- Charlotte E. Teunissen
- Alzheimer Center Amsterdam, Amsterdam Neuroscience - Neurodegeneration
- John E. Harrison
- Alzheimer Center Amsterdam, Amsterdam Neuroscience - Neurodegeneration
- Philip Scheltens
- Alzheimer Center Amsterdam, Amsterdam Neuroscience - Neurodegeneration
- Ralph A. Nixon
- Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research
- DOI
- https://doi.org/10.1038/s41467-022-32944-3
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 15
Abstract
The authors show in an animal model and in a study in patients with dementia with Lewy bodies (DLB) that the drug neflamapimod has potential to treat diseases, such as DLB, associated with loss of neurons that produce the neurotransmitter acetylcholine.
